Biogen/Ionis’ Tofersen Wins Accelerated Approval In ALS Subgroup – A Significant But Narrow Precedent
Executive Summary
US FDA designates ongoing ATLAS trial in presymptomatic individuals with SOD1 mutation as confirmatory study. ‘Classic Biogen’ approval is first in ALS under the expedited pathway and could lead to more drugs reaching market on basis of a reduction in plasma neurofilament light chain concentration.
You may also be interested in...
US FDA Neuroscience Office In Spotlight With Donanemab Delay, Relyvrio Trial Failure
Lilly’s surprise announcement that the Alzheimer’s drug is going to an advisory committee, followed minutes later by Amylyx’s disclosure that its ALS drug failed a Phase III study, marked a one-two punch of bad news for the Office of Neurosciences’ recent use of regulatory flexibility.
Biogen’s Singhal Offers A Look Into Company's Pipeline Review
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan
The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.